INMB Stock Forecast: INmune Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for INmune Bio, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores INmune Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
INMB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INMB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Freedom Broker | Maintains | Buy | $4.00 → $2.50 |
| 11 Mar 2026 | LUCID CAPITAL MARKETS | Upgrade | Buy | $2.00 → $9.00 |
| 2 July 2025 | Maxim Group | Maintains | Buy | — |
| 1 July 2025 | BTIG | Downgrade | Neutral | — |
| 1 July 2025 | Scotiabank | Downgrade | Sector Underperform | — |
| 13 Feb 2025 | Maxim Group | Maintains | Buy | — |
| 11 Feb 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 21 Oct 2024 | Alliance Global Partners | Initiates | Buy | $20 |
| 27 Sept 2024 | Raymond James | Initiates | Outperform | $18 |
| 22 Aug 2024 | Scotiabank | Initiates | Sector Outperform | $22 |
| 1 June 2023 | Baird | Initiates | Outperform | — |
| 24 May 2022 | B. Riley Securities | Downgrade | Neutral | — |
| 24 May 2022 | BTIG | Maintains | Buy | — |
| 24 Jan 2022 | B. Riley Securities | Maintains | Buy | — |
| 21 Apr 2021 | B. Riley FBR | Initiates | Buy | — |
| 21 Apr 2021 | B. Riley Securities | Initiates | Buy | — |
| 25 Nov 2020 | BTIG | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 25 Nov 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INMB.
This page is one stock. Monday covers all of them.
INMB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
INMB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, INmune Bio, Inc. returned −44.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
INMB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 553.6×
- Price / book
- 1.4×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −76.7%
- Return on assets
- −40.5%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
INmune Bio, Inc. has a market value of $27.7M and an enterprise value of $12.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$18.4M.
Free cash flow in the twelve months to 30 June 2026: −$15.7M.
INmune Bio, Inc. employs 21 people.
Data provided by Twelve Data
INMB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at INMB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own INmune Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about INMB
What is the INMB stock price forecast for 2026-2027?
The median 12-month analyst price target for INmune Bio, Inc. is $8, with estimates ranging from $2.5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is INMB stock a buy right now?
Of the 3 analysts covering INmune Bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INmune Bio, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank INMB?
As at 21 Nov 2026, INmune Bio, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
Will INMB stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $8, and Ticker Nerd's factor model ranks INmune Bio, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the INMB stock forecast for 2030?
No analyst covering INmune Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $9 over the next 12 months.
How has INMB stock performed over the past year?
INmune Bio, Inc. returned -44.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does INmune Bio, Inc. do?
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform.
About INmune Bio, Inc.
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform. The company’s programs are aimed at hematologic malignancies, solid tumors, chronic inflammation, and neurological conditions such as Alzheimer’s disease and treatment-resistant depression. INmune Bio Inc. works through a precision medicine approach, matching mechanisms of action to patient biology and clinical outcome measures. Headquartered in Boca Raton, Florida, the company operates in the biotechnology and immunology markets and focuses on advancing therapies that harness the body’s own immune response to fight disease.
CEO Mr. David J. Moss M.B.A. · 21 employees · United States · https://www.inmunebio.com